Drug major Cipla on Friday said its consolidated net profit increased 12 per cent to Rs 797 crore for the second quarter ended September 30.
The Mumbai-based drug maker had reported a consolidated net profit of Rs 709 crore in the July-September period of the previous fiscal.
Its total revenue from operations rose to Rs 5,829 crore for the September quarter from Rs 5,520 crore in the year-ago period, Cipla said in a regulatory filing.
In respect of the transfer of India-based US business undertaking, the board decided not to proceed with the proposed transfer, considering various factors, including the current operating environment, it added.
Shares of the company were trading 0.5 per cent up at Rs 1,154.10 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)